Researchers constructed MSLN-targeted CAR-NK cells and reported that MSLN-CAR-NK cells, in combination with a stimulator of interferon genes (STING) agonist, could effectively eliminate MSLN-positive human pancreatic cancer cells in the AsPC-1 cell line. This evidence concerns the gene MSLN and pancreatic neoplasm.